ABSTRACT
INTRODUCTION
Although there have been lots of important improvements in the treatment of acute myeloid leukemia (AML) during the past 30 years, disease free survival rate is still below 50%. Mortalities are induced by the progress of the disease due to the resistance to chemotherapeutics and the complications of the treatment (1) . The complete remission (CR) rate of 38 patients treated in our clinic [idarubicin 12 mg/m2 (3 days)] between 1992 and 1999 was 71%, and overall survival (OS) for 12 months was 40% and for 36 months was 23% (2) . In this study we observed that most of the patients died during the first year and many prior to the first two induction treatments due to infections arising from acute mucositis and extended myelotixicity. That is why we decided to decrease severe infections due to mucositis and myelotoxicity that are secondary to chemotherapy. In order to do this we first decreased the idarubicin dose from 12 to 8 mg/m2/day and secondly started parenteral nutrition on patients the oral intake of which had decreased. In this study, our aim was to compare the results of two different dosage of idarubicin (12 mg/m2 versus 8 mg/m2) therapy for newly diagnosed AML (FAB classification) patients.
MATERIALS AND METHODS
The study included 68 patients with AML treated between February, 1998 and January, 2005. Morphological assessment was performed according to French-AmericanBritish (FAB) classification. Leukemia diagnosis was performed in the patients who had blast over 30% in their bone marrow aspiration samples. Bone marrow samples were stained with Wright-Giemsa, PAS, Sudan black and esterase stainings. Hepatomegaly, splenomegaly, lymphadenopathy and bleeding detected in the physical examination of all patients were recorded. Routine blood counts were also performed. Liver and renal function tests, flow cytometric examination, monoclonal antibodies and OS, event-free survival (EFS), disease free survival (DFS) were assessed. If blast rate was below 5% in the bone marrow, complete remission and if that was between 5-20%, partial remission was determined. The drugs used in the treatment of AML on group I is shown in Table 1 . For Group II, the dosage of idarubicin (8 mg/ m2/day, 3 doses) was reduced at induction phase I-II and TPN was begun.
This study was prospective and has been approved by the local ethics committee and written informed consent of all parents were taken.
Statistics tests
Statistical analyses were performed by SPSS 10.0 pack program. Chi-square and Kaplan Meier tests were applied for the evaluation of the data. p≤0.05 was considered as statistically significant. was 85.3±46.9 months (range 6-168 months). There were 26 patients (38.2%) in group I and 42 (61.8%), in group II. The complications that occurred during therapy can be seen in Table 2 . These complications were mostly seen during induction phase I. The complications were relatively less during the other phases. In induction and consolidation phases including intensive therapies; neutropenia, febrile neutropenia and mucositis were the most common complications. The most common complication was respiratory tract infection and the second was neutropenia during the maintenance therapy. After the first induction therapy of patients in group I, complete remission (CR) was achieved in 16 patients (61.5 %) and partial remission (PR), in 4 patients (15.4%). Six cases (23.1%) had died due to the complications during therapy. Total (CR+PR) remission rate was 76.9%. Seven patients (26.9%) completed chemotherapy protocole and they were followed without chemotherapy (17-63 month) after maintenance. For one of the patients secondary aplasia developed and he died due to the infectious complication at the 17th month without chemotherapy. As a result, 6 cases (23.1%) are being for 12 months, 34/54% for 24 months, 29/48% for 36 months. EFS were 43/65% for 12 months, 34/50% for 24 months, and 29/50% for 36 months. DFS were 44/62% for 12 months, 34/51% for 24 months, and 29/51% for 36 months (Figure 1-3 ). When survival rates were compared between two groups, the difference of OS and DFS rates were statistically significant (Breslow, TaroneWare), but the difference of EFS rates were not statistically significant.
RESULTS

Out
DISCUSSION
Many patients with AML had died during intensive induction therapy. Idarubicin 12 mg/m2/day, 3 doses was changed to 8 mg/m2/day, 3 doses. Our aim was to reduce deep neutropenia and serious infections during the first treatment, and reduce infectious complications, and treat the AML. It is reported that relapse developed in 30-40% of newly diagnosed children with AML. The prognosis of patients who had developed relapse in 18 months were worse than the patients who were newly diagnosed, and also they had shorter remissions than those who were newly diagnosed (3) (4) (5) (6) (7) (8) . Relapse had developed approximately after the first year in the patients that we followed up in our clinic and then their induction phase I treatments were modified. As we could not manage these relapsing patients to enter remission, they began to die. That's why we have to take precautions for these patients in order to prevent relapse. Because it is very difficult for patients that develop relapse to enter into remission again. Damon et al. (9) reported that the CR rate was 51% in 138 AML patients and TRM rate was 11%. Virchis et al. (10) applied fludarabine, cytarabine and granulocyte colony stimulating factor (FLAG regimen) to one of their treatment groups, and additionally idarubicine (FLAG-IDA regimen) to another group of 105 AML and MDS patients. The researchers were able to find no statistically significant difference between the two groups. They have achieved a CR of 59% during the study period of 4 years. They have recorded that EFS was 23% (range 11 months-5 years). In addition, Dluzniewska et al. (11) reported that the 3 year-OS for all disease groups was 61%; EFS, 54%; in the standard risk group OS was 81% and EFS was 70%; and in high risk group OS was 40% and EFS was 40%. The research investigated that the remission rate was 79% in whole group (98% in standard risk group and 63% in high risk group).
O'Brien et al. (12) administered daunomycine to one group of patients (group 1) and idarubicin to the other (group 2) in their research involving 268 patients with AML. They also administered idarubicin in two different dosages as 10 mg/m2 (group 2a) and 12 mg/m2 (group 2b). When they compare all three groups, there is no statistically significant difference in 5-year EFS and OS. In group 1, EFS was 50% and OS was 56%; in group 2a, EFS was 50% and OS was 60%; and in group 2b, EFS was 34% and OS was 50%.
Seo et al. (13) treated 125 newly diagnosed AML patients between 1983 and 1998. They began to administer more intensive therapy in 1990s than 1980s. They recorded that the CR rate was 58% for all patients. Six-year OS and DFS rates were 22% and 28% for patients with CR. They noticed that the CR and OS rates were better and statistically significant in 1990s when compared to those of 1980s [CR was 69% and 54%, respectively (p=0.0016); OS was 32% and 15%, respectively (p=0.0014)]. Early deaths occured in the first 30 days and they were 9% in 1990 and 26% in 1980. Considering these findings, they reported that the difference was statistically significant. However, they were not able to report any significant improvement in DFS rates. Creutzig et al. (14) published the results of their multicentric study including 471 children received AML BFM 93 treatment protocol. Of these 471 patients, 161 were in standard risk group and 310 were in high risk group. They used daunorubicin or idarubicin together with cytarabine plus etoposide. They achieved remission in 87% of the patients. Fiveyear survival was 60%, EFS was 51%, and DFS was 62% in this patient population In the examination of bone marrow on the 15th day, blast>5% was observed in 17% of the patients of idarubicin group, while it was observed in 31% of daunorubicin group (p=0.007). When they compared AML BFM 93 to 87 protocols, they found that 5-year remission rates were 78% versus 68% and EFS rates were 44% versus 31% (p=0.01). They did not find any significant difference between the 5-year EFS and DFS rates of daunorubicin and idarubicin groups. In a current study OS and DFS rates were statistically significant (Breslow, Tarone-Ware), but EFS rates were not between two groups.
In conclusion, the survival of children with AML is still low; under 5 years, and we suggest that we can get better results by the protocol with idarubicin dose of 8 mg/ m2/day. And we suggest that nutrition is important in patients with AML, if oral intake has impared particularly due to mucositis, TPN conduction can reduce mortality and morbidity. However, we suggest that preventive care should be conducted for the patients not to develop relapse.
